Citations

Clear

4207 citation(s) found for "Chen, Yu".

A human-in-the-loop explanation framework for morphologically transparent AI predictions from whole-slide images
Lou, Peiliang , Zhu, Yitan , Kumari, Roopa, Yang, William , Wang, Y. Claire , Guo, Ruifemg, Goode, Ellen, Huang, Yajue, Han, Wenchao, Feng, Tianshu , Wang, Chen, Zhu, Yitan , Chia, Nicholas , Yang, William, Wang, Yan, Novotny, Brenna C. , Winham, Stacey J. , Goode, Ellen L. , Han, Wenchao, Wang, Chen

Mayo Clinic

No container title available | January 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.01.27.701796 Get It

Abstract Deep learning models enable the prediction of clinical endpoints from whole-slide images (WSIs), but many such models function as “black boxes”, lacking transparency about whether and which histomorphological patterns drive their predictions, hindering interpretability and clinical adoption. Here we propose a human-in-the-loop explanation framework, MorphoXAI, which provides both local and global interpretability for deep learning models by incorporating human-expert interpretations. At the global level, it reveals the histomorphological patterns on which the model consistently relies to distinguish between classes of WSIs, as well as the patterns associated with confusion between classes. At the local level, it indicates which of these patterns are used in the prediction of an individual WSI and which regions within the slide correspond to such patterns. We validated our method on a deep learning model trained for ovarian tumor histologic subtype prediction. The results show that our framework generates explanations that accurately reflect the histomorphology underlying the model’s predictions at both global and local levels. For interpretability and clinical utility in diagnostic contexts, human evaluation results showed that our explanations were easy to interpret, rich in diagnostic features, and directly helpful for diagnostic decision-making, thereby enhancing pathologist-AI collaboration. Our work highlights that unifying global and local explanations and grounding them in expert-interpreted morphology enhances the interpretability and verifiability of deep learning models, thereby facilitating the transparent deployment of such models in clinical practice.
Mapping Microvascular Flow via Radon Transform Ultrasound: Technical Advances and Pilot Application
Yin, Jingyi , Huang, Lijie, Zhang, Jingke , DeRuiter, Ryan M., Zhu, Xiang-yang, Krier, James D., Kim, Y, Zhao, Y., Ji, Kaipeng , Lerman, L. O., Chen, S., Huang, Chengwu , Zhao, Yanzhe , Huang, Chengwu , Zhang, Jingke , Huang, Lijie, Lok, U‐Wai , DeRuiter, Ryan M. , Lucien, Fabrice , Lerman, Lilach O.

Mayo Clinic

BME Frontiers | January 30, 2026 | Volume: 7 | Issue: No issue available | Pages: No page available

10.34133/bmef.0234 | PMID 42317226 Get It

Objective: This study aims to develop a contrast-free, high-sensitivity ultrasound method, denoted as Radon transform-based flow measurement (R-Flow), for in vivo mapping of microvascular flow vectors and for establishing R-Flow-derived vector-field metrics to noninvasively quantify microcirculatory patterns in liver cirrhosis. Impact Statement: R-Flow enables robust, contrast-free imaging of microvascular dynamics and demonstrates translational feasibility in the human liver. Its direction-aware indices offer pilot in vivo quantification of flow redistribution and remodeling, providing unique insights into hepatic flow dynamics. Introduction: Microvascular dysfunction is a hallmark of many diseases, yet noninvasive visualization and quantitative assessment of abnormal microcirculation remain limited. Methods: R-Flow leverages Radon transform to decode red blood cell dynamics from the spatiotemporal domain of ultrasound flow signals, reconstructing velocity vectors at microvascular scale. From these vector maps, unique direction-aware indices are further derived to characterize flow distribution and heterogeneity. Results: Validated across simulations, phantoms, and in vivo studies, R-Flow provides robust velocity estimation across a wide range (1 to 60 mm/s). Notably, it enables high-sensitivity microvascular flow vector mapping of human liver, showing strong agreement with references ( r > 0.9). In a rat model, these direction-aware indices revealed a shift from healthy multipath perfusion in control livers to directionally biased vascular pattern in cirrhotic livers, demonstrating significant correlation with pathological indicators. Conclusion: R-Flow enables noninvasive, contrast-free mapping of microvascular blood flow velocity and offers a promising approach for high-resolution assessment of microvascular flow characteristics.
Abstract DP020: Quantification of Hematoma and Perihematomal Edema Volumes in Intracerebral Hemorrhage The QUANTUM Randomized Clinical Trial
Ironside, Natasha , Patrie, James, Kumar, Jeyan S. , Naamani, Kareem El, Abbas, Rawad , Becerril, Andrea Pecina, Chen, Ching-Jen, Rizvi, Tanvir , Mastorakos, Panagiotis , Naamani, Kareem El , Snyder, M. Harrison

Mayo Clinic

Stroke | January 29, 2026 | Volume: 57 | Issue: Suppl_1 | Pages: No page available

10.1161/str.57.suppl_1.dp020 Get It

Introduction: Optimizing patient selection and time-to-intervention will be crucial to the success of future clinical trials seeking to implement therapies and improve intracerebral hemorrhage (ICH) patient outcomes. Automated and accurate ICH and perihematomal edema (PHE) volumetry carries significant potential to strengthen trials targeting ICH and PHE expansion. Aims: The Quantification of Hematoma and Perihematomal Edema Volumes in Intracerebral Hemorrhage (QUANTUM) trial was designed with aims of (1) validating a fully automated artificial intelligence (AI) method for supratentorial, spontaneous ICH and PHE volumetry against the manual and semiautomated quantification methods and (2) establishing a model framework for the translation of AI technology through conduct of a clinical trial under the equivalence hypothesis paradigm. Methods: This trial was a prospective, randomized, clinical study with blinded outcome assessment. Six independent raters were randomized in a 1:1 ratio to ICH and PHE volumetry from non-contrast CT scans in the Virtual International Stroke Trials Archive with either the semiautomated or manual quantification method. The primary outcomes were equivalence between (1)ICH volume measurements on admission (<24h from symptom onset) for the manual versus the fully automated or the sem-automated quantification methods, and (2)PHE volume measurements on day 3 (72±12h from symptom onset) for the manual versus the fully automated or the semiautomated quantification methods. The required sample size was 126 ICH and 126 PHE measurements, based upon a significance level of 0.025 to account for the two equivalence tests. Results: The geometric mean relative discrepancies between the fully automated and the manual ICH and PHE volume measurements did not cross the pre-specified 10% equivalence margin. The geometric mean relative discrepancies between the semiautomated and the manual ICH and PHE volume measurements did cross the pre-specified 10% equivalence margin. The fully automated method (mean 10.0±2.7s/scan) was significantly faster than the manual (mean 189±199 s/scan; P <0.001) and semiautomated (mean 79±68s/scan; P <0.001) methods. Conclusions: ICH and PHE volumes quantified by AI could replace clinician measurements within a 10% error margin and with substantially greater efficiency. The semiautomated method could not replace manual measurements. This trial demonstrated feasibility of the equivalence hypothesis framework for AI validation studies.
Abstract DP154: The Association Between Comprehensive Evaluation in ESUS and Stroke Recurrence: A secondary analysis of the Cardiac Abnormalities in Stroke Prevention and risk of Recurrence Study
Stretz, Christoph, Lewis, Skylar, Chahien, Dalia, Eklund, Kelsey , Khasiyev, Farid, Kasab, Sami Al, D'Souza, Marissa, Kerrigan, Deborah , Sharma, Richa, Nour, Hassan Osama Mostafa Aboul, Nahab, Fadi, Omran, Setareh Salehi , Linares, Guillermo , Sehgal, Siddharth, Singh, Eesha , Zha, Alicia , Mannion, Shani, Chen, Lucia , Thompson, Sean, Thon, Jesse, Penckofer, Mary , Yu, Wenzheng, Qdais, Ahmad Abu, Dumitrascu, Oana, Talat, Fawad , Kang, Jieun, Aziz, Yasmin, Zubair, Adeel , Havenon, Adam de, Bowman, Anna , Shahrivari, Mahan, Liebeskind, D, Nedelcu, Simona , Ali, Hamid , Kam, Wayneho , Nguyen, Thanh N., Herpich, Franziska , Farooqui, Mudassir, Rojas-Soto, Diana , Yaghi, Shadi, Khan, Fahad , Stretz, Christoph , Siegler, James E. , Lineback, Christina , Kasab, Sami Al , Culbertson, Collin J , D’Souza, Marissa , Stamm, Brian , Ro, Jennifer , Sharma, Richa , Nour, Hassan Aboul , Peter, Shani , Thon, Jesse , Jillella, Dinesh , Sloane, Kelly L , Aziz, Yasmin , Brorson, James R. , Farooqui, Mudassir

Mayo Clinic

Stroke | January 29, 2026 | Volume: 57 | Issue: Suppl_1 | Pages: No page available

10.1161/str.57.suppl_1.dp154 Get It

Background: Although the embolic stroke of undetermined source (ESUS) construct was proposed as a unifying concept for embolic-appearing strokes without an identified cause, it includes patients with diverse and often unrecognized underlying mechanisms. This study investigates the differential rate of recurrent stroke according to the completeness of neurodiagnostic testing in a diverse multicenter cohort. Methods: This was a retrospective analysis of a multicenter observational cohort study (n=27 sites). Patients with ESUS were categorized into three groups: (1) established mechanism after further work up (ESUS-E), (2) patients who underwent a comprehensive diagnostic workup without an identified etiology (ESUS 2.0), and (3) no advanced workup (ESUS-NAW). The primary outcome of recurrent ischemic stroke was assessed by comparing ESUS 2.0 to both ESUS-E and ESUS-NAW groups using adjusted Cox proportional hazards models. Results: Of the 2,281 patients included, 694 (30%) were classified as ESUS-E, 344 (15%) as ESUS 2.0, and 1,443 (55%) as ESUS-NAW. The ESUS 2.0 group had a significantly lower annualized recurrence rate (1.98 per 100 person-years) compared to both the ESUS-NAW group (7.7 per 100 person-years; aHR 0.27, 95% CI: 0.11–0.62; p=0.002) and the ESUS-E group (6.10 per 100 person-years; aHR = 0.35; 95% CI 0.15–0.85, p=0.020). Within the ESUS-E group, cancer (aHR 5.33; 95% CI: 2.09–13.63; p < 0.001) and non-stenosing atherosclerotic disease or arch atheroma (aHR 3.40; 95% CI: 1.18–9.83; p = 0.023) were associated with significantly increased risk of recurrence when compared to ESUS 2.0. Conclusion: These findings demonstrate a lower risk of recurrent stroke in patients classified as ESUS 2.0, diverging from the 5–6% annual recurrence rates observed in prior ESUS trials. These findings suggest that patients who receive comprehensive diagnostic evaluation without identification of a specific etiology have a lower risk of recurrent stroke, an important consideration for the design of future ESUS studies.
Treatment effect of neoadjuvant immunotherapy in melanoma correlates with tumor burden: meta-analysis of reported clinical trials
Duarte-Bateman, Daniela, Shen, A., Ko, Jennifer, Melenhorst, Jan Joseph, Tufaro, Anthony P. , Kennedy, Lucy Boyce , Isaacs, James, Gastman, Brian , Escandón, Joseph M. , Chen, Yanwen , Isaacs, James

Mayo Clinic

Melanoma Research | January 29, 2026 | Volume: 36 | Issue: 2 | Pages: 98-106

10.1097/cmr.0000000000001079 | PMID 41607207 Get It

Neoadjuvant immune checkpoint inhibition (Neo-ICI) in melanoma is an emerging therapeutic strategy that induces pathologic responses with significant prognostic implications for survival. Tumor burden in nonresectable melanoma has a major impact on immunotherapy efficacy, yet little is known on its impact in the Neo-ICI setting. We evaluated the association between tumor burden, measured by the sum of diameters (SoD), and pathological response in melanoma patients treated with Neo-ICI. A meta-analysis of published trials in resectable stage III/IV melanoma was conducted, extracting data on patient characteristics, treatment regimens, pathological response, and survival outcomes. A total of 451 patients were included in the meta-analysis. The pooled pathological complete response (pCR) rate was 47% (95% confidence interval: 35–58%; P < 0.001). Meta-regression demonstrated a significant association between SoD and pCR (moderator = −0.36; P = 0.032), with greater tumor burden associated with lower pCR rates. No significant association was observed between SoD and recurrence-free survival (RFS). This study identifies higher tumor burden as a potential risk factor for lower pathologic response rates to neoadjuvant therapy, underscoring the need to incorporate tumor burden into future clinical research and potentially clinical decision-making.
The Association Between the C-Reactive Protein-Albumin-Lymphocyte Index and Gallstone Disease: A Cross-Sectional Study
Liu, Xingxing , Li, Kang , Zeng, Yonghua , Ying, X.N. , Zhao, Yu , Zhou, Xiaodong , Chen, Youxiang , Zeng, Chunyan , Zhu, Liang , Luo, Yixing , Chen, Youxiang , Ying, Xiaolong

Mayo Clinic

Clinical and Translational Gastroenterology | January 26, 2026 | Volume: 17 | Issue: 3 | Pages: e00979

10.14309/ctg.0000000000000979 | PMID 41586504 Get It

INTRODUCTION: This study used the novel C-reactive protein-albumin-lymphocyte (CALLY) index to explore its relationship with the risk of developing gallstones. METHODS: This study conducted a cross-sectional analysis of the National Health and Nutrition Examination Survey data from 2017 to 2020; multivariable logistic regression examined the CALLY-gallstone association. Restricted cubic splines tested nonlinearity. Subgroup and mediation analyses explored population variations and mediating effects (Conicity, lipid accumulation product, and a body shape index). Receiver operating characteristic curves compared CALLY, systemic immune inflammation index, systemic inflammatory response index, and aggregate index of systemic inflammation predictive performance. RESULTS: After comprehensive adjustments, the highest CALLY quartile had significantly lower gallstone risk vs the lowest (odds ratio 0.56, 95% confidence interval 0.34–0.94). Restricted cubic splines revealed a linear inverse correlation. Subgroup analyses generally supported this inverse relationship. Mediation analysis identified the Conicity index as the strongest mediator (21.47%, P < 0.001), followed by lipid accumulation product and a body shape index (10.72% each, P < 0.001). Receiver operating characteristic analysis showed CALLY (area under the curve = 0.604) outperformed systemic immune inflammation index (0.540), systemic inflammatory response index (0.550), and aggregate index of systemic inflammation (0.546). DISCUSSION: A significant inverse association exists between the CALLY index and gallstone prevalence. The CALLY index demonstrates superior predictive ability compared with other indices, suggesting its potential utility as an objective biomarker for early gallstone risk identification.
AI-generated data contamination erodes pathological variability and diagnostic reliability
He, Hongyu , Xiang, Shaowen, Zhang, Y. P. , Zhu, Yingtao, Zhang, Jin, Lu, Yunyi, Deng, Hao, Alsentzer, Emily, Chen, Qingyu, Yu, Kun‐Hsing , Marshall, Andrew, Chen, Tingting, Anumasa, Srinivas, Ebner, Daniel, Ho, Dean, Cheng, Ching-Yu, Liu, Dianbo, Deng, Hao , Alsentzer, Emily , Liu, Yun , Chen, Qingyu , Yu, Kun‐Hsing , Chen, Tingting, Anumasa, Srinivas, Ebner, Daniel, Ho, Dean , Ngiam, Kee Yuan , Cheng, Ching-Yu

Mayo Clinic

No container title available | January 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.01.19.26344383 Get It

Abstract Generative artificial intelligence (AI) is rapidly populating medical records with synthetic or partially AI-generated content, creating a feedback loop where future models are increasingly at risk of training on uncurated AI-generated data. However, the clinical consequences of this AI-generated data contamination remain unexplored. Here, we show that in the absence of mandatory human verification, this self-referential cycle drives a rapid erosion of pathological variability and diagnostic reliability of medical data at population scale. By analysing more than 800,000 synthetic data points across clinical text generation, vision–language reporting, and medical image synthesis, we find that models progressively converge toward generic phenotypes regardless of the model architectures. Specifically, rare but critical findings, including pneumothorax and effusions, vanish from the synthetic content generated by AI models, while demographic representations skew heavily toward middle-aged male phenotypes. Crucially, this degradation is masked by false diagnostic confidence. Models continue to issue reassuring reports while failing to detect life-threatening pathology, with false reassurance rates tripling to 40%. Blinded physician evaluation confirms that this decoupling of confidence and accuracy renders AI-generated documentation clinically useless after just two generations. We systematically evaluate three mitigation strategies that can be easily integrated into existing clinical workflows, finding that while synthetic volume scaling fails to prevent collapse, mixing real data with quality-aware filtering effectively preserves diversity. Ultimately, our results suggest that without policy-mandated human oversight, the deployment of generative AI threatens to degrade the very healthcare data ecosystems it relies upon.
Phase 1b/2 study of BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancer
Folprecht, G., Varghese, Anna M. , Gutiérrez, Martín , Noel, Marcus Smith , Chen, Eric, Dayyani, Farshid, Davis, S Lindsey, BasuMallick, Atrayee, Garrido-Laguna, Ignacio, Osawa, Mayu, O’Brien, Shaun, Novosiadly, Ruslan D., Xu, Ke, Greenawalt, Danielle , Dutta, Santanu, Victor, Christina Twyman Saint, Lenz, Heinz-Josef, Folprecht, Gunnar , Chen, Eric , Osawa, Mayu , Le, Dung Thi , Trikalinos, Nikolaos A. , Chen, Eric X. , Dayyani, Farshid , Davis, S Lindsey, Wee, Wen , Garrido‐Laguna, Ignacio , O’Brien, Shaun, Dutta, Santanu , Victor, Christina Twyman-Saint , Lenz, Heinz‐Josef

Mayo Clinic

Journal for ImmunoTherapy of Cancer | January 22, 2026 | Volume: 14 | Issue: 1 | Pages: e011284

10.1136/jitc-2024-011284 | PMID 41571299 Get It

Background Cysteine–cysteine chemokine receptors 2 (CCR2) and 5 (CCR5) contribute to immune suppression in tumor microenvironments. CCR2 and CCR5 antagonists have demonstrated antitumor activity in pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC), respectively. This phase 1b/2, open-label study evaluated BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy±nivolumab in advanced PDAC or metastatic CRC. Methods Part 1 included patients with metastatic untreated (first-line (1L)) PDAC, 1L CRC, or previously treated (second or third line (2/3L)) microsatellite stable (MSS) CRC. Patients received 2 weeks of BMS-813160 monotherapy (300 mg two times a day, 600 mg once daily, 300 mg once daily, or 150 mg once daily) and then BMS-813160+chemotherapy (gemcitabine+nab-paclitaxel (gem/nabP; 1L PDAC), 5-fluorouracil+leucovorin+irinotecan (FOLFIRI; 1L CRC)), or nivolumab (2/3L MSS CRC). Part 2 included patients with metastatic 1L PDAC or 2L CRC. Patients received BMS-813160 300 mg two times a day+gem/nabP±nivolumab (1L PDAC), BMS-813160 300 mg two times a day or 150 mg once daily+FOLFIRI (2L CRC), or chemotherapy alone. Primary endpoints were safety and pharmacodynamics (Part 1) and efficacy (Part 2). Results In Part 1, 22 of 75 (29%) and 54 of 72 (72%) patients experienced a treatment-related adverse event during monotherapy lead-in and overall, respectively. Two dose-limiting toxicities (rash and pericardial effusion with pericarditis, both grade 3) occurred. In Part 2, patients with 1L PDAC who received BMS-813160 300 mg two times a day+gem/nabP+nivolumab achieved an overall response rate (ORR) of 37% (13/35); the median duration of response (DOR) was 45 weeks (95% CI 26.1 to not evaluable). ORRs with BMS-813160 300 mg two times a day+gem/nabP and gem/nabP alone were 26% (9/35) and 28% (9/32), respectively; median DORs were 121 and 31 weeks, respectively. Progression-free survival rates at 24 weeks were 56% (BMS-813160 300 mg two times a day+gem/nabP+nivolumab), 56% (BMS-813160 300 mg two times a day+gem/nabP), and 50% (gem/nabP). ORRs in 2L CRC were 19% (6/32; BMS-813160 300 mg two times a day+FOLFIRI), 13% (4/32; BMS-813160 150 mg once daily+FOLFIRI), and 27% (7/26; FOLFIRI). Conclusions In 1L PDAC, BMS-813160 300 two times a day+gem/nabP±nivolumab demonstrated durable antitumor response and was well tolerated. BMS-813160 combination regimens were tolerable in other cohorts, but clinical efficacy was not demonstrated. Trial registration number NCT03184870 .
Early graft failure after adult living donor liver transplantation: A multicenter risk analysis and development of the early allograft failure in living donor liver transplantation (EAGLE-LDLT) model
Li, Zhihao, Centonze, Leonardo , Raptis, Dimitri , Marquez, Kris Ann Hervera , Rammohan, Ashwin, Gunasekaran, Vasanthakumar , Hong, Suyoung , Chen, I Lun, KIM, Jongman , Hsu, Shih-Chao , Akamatsu, Nobuhisa, Shaked, Oren, Genedy, Lara, Dutkowski, Philipp , Nadalin, Silvio, Boehnert, Markus U, Mathur, Abhishek, Emond, J., Testa, Giuliano, Olthoff, Kim, Taner, Timucin, Wong, Tiffany CL, Hasegawa, Kiyoshi, Balci, D., Cattral, Mark, Sapisochin, G., Selzner, Nazia, Jeng, Long-Bin, Chen, Chao-Long, Suh, Kyung-Suk, Rela, Mohamed, Broering, Dieter, Clavien, Pierre-Alain, Kim, Jong Man , Raptis, Dimitri Aristotle , Li, Zhihao , Hong, Su young , Chen, I. , Centonze, Leonardo , Li, Zhihao , Rammohan, Ashwin , Chen, Itsuko Chih-Yi , Kirimker, Elvan Onur , Akamatsu, Nobuhisa , Shaked, Oren , Finotti, Michele , Yeow, Marcus , Nadalin, Silvio , Boehnert, Markus U , Polak, Wojciech G , Bonney, Glenn K , Samstein, Benjamin , Emond, Jean C , Testa, Giuliano , Olthoff, Kim M , Heimbach, Julie K , Taner, Timucin , Wong, Tiffany C L , Balci, Deniz , Cattral, Mark , Sapisochin, Gonzalo , Selzner, Nazia , Jeng, Long-Bin , Joh, Jae-Won , Chen, Chao-Long , Suh, Kyung-Suk , Di Sandro, Stefano , Rela, Mohamed , Broering, Dieter , Clavien, Pierre-Alain , Akamatsu, Nobuhisa , Shaked, Oren , Boehnert, Markus , Polak, Wojciech G. , Mathur, Abhishek , Samstein, Benjamin , Emond, Jean C. , Testa, Giuliano , Heimbach, Julie K. , Taner, Timuçin , Wong, Tiffany , Hasegawa, Kiyoshi , Cattral, Mark S. , Sapisochín, Gonzalo , Selzner, Nazia , Joh, Jae‐Won , Rela, Mohamed , Bröering, Dieter C. , Clavien, Pierre‐Alain

Mayo Clinic

Liver Transplantation | January 21, 2026 | Volume: 32 | Issue: 7 | Pages: 1027-1039

10.1097/lvt.0000000000000816 | PMID 41564353 Get It

Early allograft failure (EAF) after living donor liver transplantation (LDLT) remains a clinical challenge. Existing prediction models developed for deceased donor transplantation poorly apply to LDLT due to distinct surgical and physiological factors. This study identifies clinical determinants of EAF and develops an LDLT-specific prediction model. We conducted a multicenter retrospective cohort study from 17 high-volume LDLT centers (January 2016–December 2020) with external validation at a tertiary center in Saudi Arabia (January 2015–December 2022). The primary outcome was EAF (graft loss or patient death ≤90 d). Multivariable mixed-effects logistic regression identified preoperative/intraoperative risk factors. The EAGLE-LDLT model was constructed using postoperative laboratory values. Performance was compared against established models (EAD, MEAF, A2ALL) using ROC analysis and decision curve analysis. The development cohort included 2944 adult LDLT recipients (67.7% male; median age 55 y; median MELD 14) with a 5.5% EAF rate. External validation included 1020 recipients (median MELD 21, 6.7% EAF). Independent risk factors for EAF were MELD (OR 1.06, 95% CI 1.04–1.08), donor BMI (OR 1.05, 95% CI 1.00–1.10), portal vein thrombosis (OR 1.73, 95% CI 1.13–2.63), and hepaticojejunostomy (OR 1.58, 95% CI 1.06–2.36). The EAGLE-LDLT model incorporating peak ALT (>468 U/L), peak INR (>1.9), and bilirubin (>3.5 mg/dL) and INR (>1.3) at POD7, demonstrated superior discrimination (AUC=0.81) compared with MEAF (AUC=0.77, p =0.004), EAD (AUC=0.67, p <0.001), and A2ALL (AUC=0.65, p <0.001). EAGLE-LDLT achieved balanced sensitivity (75.0%) and specificity (73.7%), effectively stratifying patients into high-risk (15% of patients; 40.4% EAF incidence) and low-risk groups. Preoperative and intraoperative clinical factors predict EAF in LDLT. The EAGLE-LDLT model accurately identifies LDLT recipients at the highest risk for EAF postoperatively.
Radiographically-Measured Sarcopenia Predicts Hospitalization in Patients With Crohn’s Disease
Bali, Aman, Sheikh, Walaa G. El , Ouni, A. El , Moktan, Varun , Chen, Frank, Farraye, Francis A, Tamim, Hani, Jana, Hashash, Bali, Aman S. , Bali, Aman , Ouni, Ahmed, Kwon, Joshua , Farraye, Francis A. , Tamim, Hani

Mayo Clinic

Journal of Clinical Gastroenterology | January 21, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/mcg.0000000000002317 | PMID 41564027 Get It

Background and Aims: Sarcopenia (SP) is increasingly recognized as a poor prognostic factor for patients with Crohn’s disease (CD). We aimed to use radiographically-measured SP to determine a disease-specific definition and measure its association with CD-related outcomes. Methods: This retrospective study included adults with CD seen at our outpatient tertiary center between 2019 and 2021 who underwent a CT scan within 3 months of visit. Using axial cross-sectional measurements at the L3 vertebral level, skeletal muscle area was indexed to height to derive skeletal muscle index (SMI). Demographics, comorbidities, CD phenotype, and outcomes, including hospitalization at 1 year, were analyzed in univariate and multivariate models. Results: One hundred twenty-four patients with CD were included, with a mean age of 52.2±16.6 years and 53.2% (66/124) women. Overall, 33.1% (41/124) had SP based on sex-specific cutoffs with men representing 75.6% (31/41) of the sarcopenic population. In bivariate analysis, patients with SP had a higher likelihood of hospitalization (43.9% vs. 22.9% for non-SP, P =0.02) and penetrating CD phenotype (20.0% vs. 2.3% for non-SP, P <0.05). On multivariate regression, higher SMI was associated with decreased hospitalization, with each 10-unit increase in SMI conferring 0.54 lower odds (OR: 0.54 [95% CI: 0.32-0.92], P =0.02). Patients with higher SMI trended towards lower use of biologics (OR: 0.70 [95% CI: 0.45-1.09], P =0.12). Our novel SP definition derived from an IBD population performed similarly to definitions from the literature. Conclusion: Our study demonstrates the application of an automated algorithm for the quantification of body composition based on CT scan in patients with CD. SP and low SMI were associated with increased hospitalization at 1 year.